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The predicted protease cleavage site (p7/pl; [J. Virol. 66 (1992) 185618651) within the nucleocapsid precursor protein (~15) of human immunode- 
ficiency virus, type 1, was confirmed using an in vitro assay employing recombinant HIV-l protease and a chemically synthesized 72 amino acid 
polypeptide containing the p7 and pl protein domains of the native gag polyprotein. The cleavage occurred between amino acid 55 (N) and amino 
acid 56 (F) of the polypeptide, as determined by N-terminal sequencing. The hydrolysis was optimal at pH 6.0 and at high salt concentration. The 
kinetic parameters kY,,,,. k,, and k,JK,,, were 99 PM (+S), 0.152 s-’ (? 0.002) and 1.56 mM-’ . s-’ (k 0.1 l), respectively. Reconstituted as well as 
denatured polypeptides were cleaved at approximately the same rate, demonstrating that the conformation of the p7 protein, as a result of the 
Zr?‘-binding, had no significant effect on the rate of hydrolysis of the p7/pl cleavage. 
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1. INTRODUCTION 
The human immunodeficiency virus, type 1 (HIV-l), 
genome is translated into the Pr165e”g~p”’ and Pr55g”g 
polyproteins [l], which are ultimately cleaved by the 
viral protease (PR). Cleavage of Pr55gag enerates the 
mature structural proteins, ~17, ~24, p7 and p6, found 
in the virus; p17 represents the matrix antigen (MA), 
p24 the core antigen (CA), and p7 the nucleocapsid 
(NC) protein (for review see [226]). Recently, two small 
proteins, p2 and pl, have been identified in HIV prepa- 
rations, the respective coding sequences of which align 
up-stream and down-stream of the p7 region in the 
HIV-l genome [7,8]. This raised the question of whether 
these small proteins represent products of the matura- 
tion event characterized by the polyprotein processing 
by the HIV PR. Synthetic oligopeptides corresponding 
to the p2/p7 cleavage site were readily cleaved in vitro 
by PR [9,10]. These two arguments, specific in vitro 
cleavage by HIV PR and identification of the products 
in mature viruses, classifies the pup7 as a maturation 
site. However, a synthetic 1 l-amino acid oligopeptide 
spanning the predicted p7/pl site was cleaved neither by 
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HIV-l PR nor by HIV-2 PR. This could indicate that 
pl is generated by cellular proteases or, as was sug- 
gested, sequences additional to the p7/pl cleavage site 
are necessary for this processing [lo]. In this report, we 
confirm and characterize the specific in vitro cleavage 
of the p7/pl site of a chemically synthesized 72-amino 
acid polypeptide containing the p7 and pl protein do- 
mains by recombinant HIV-l PR. 
2. MATERIALS AND METHODS 
A 72-amino acid polypeptide containing the p7 and pl protein 
domains was chemically synthesized as previously published [l 11. The 
lyophilized powder was dissolved in 10 mM DTT at a concentration 
of 50 mg/ml, aliquoted under nitrogen and stored in a sealed tube at 
-8O’C. 
HIV-1 PR was obtained as a solution of 5 ,ug/ml in 50 mM 2- 
morpholinoethanesulfonic a id (MES) buffer, pH 6.5, containing 5% 
glycerol, 1 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM 
dithiothreitol (DTT) as described [12]. 
Protease assays containing 5 pg of denatured 72-amino acid poly- 
peptide (without Zn’+) as substrate were carried out in the presence 
of 6 nM HIV-1 protease at 37’C in buffer A (250 mM potassium 
phosphate, pH 6.0, 750 mM ammonium sulfate, 1 mM dithiothreitol 
(DIT), 1 mM EDTA, 10% glycerol) in a total volume of 10 ~1. 
Reactions were terminated by adding 90~1 of 1% tri-fluoroacetic acid 
(TFA) and subjected to RP-HPLC on a DELTA PAK Cd-300 8, 
column (Waters) using a gradient of 2&30% acetonitrile in 0.05% 
TFA over 6 min followed by a 2 min gradient of 3(r32% acetonitrile. 
Control reactions employing a synthetic nona-peptide substrate corre- 
sponding to the p17/p24 cleavage site of HIV-l were carried out as 
described earlier [13]. The amount of products generated by prote- 
olytic cleavage were evaluated by integration of the peak areas. Pro- 
tease concentration in the assay was determined by active site titration 
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using the HIV protease inhibitor, SR 47247 (SANOFI) and by Hen- 
derson analysis [14]. For kinetic analysis, protease activity was titrated 
with the 72-amino acid polypeptide at concentrations of 47-588 ,uM 
in two independent assays incubated for 6 and 15 h, respectively. 
Kinetic parameters were determined by Lineweaver-Burk and Eadie 
Hofstee analysis. 
24 h of incubation according to the appearance of prod- 
uct peaks by RP-HPLC (Fig. 2A). Additionally, pro- 
tease inhibitors, such as JLK80/1MC, inhibited hydrol- 
ysis of the synthetic polypeptide demonstrating specific 
hydrolysis mediated by the HIV-l protease (data not 
shown). 
3. RESULTS AND DISCUSSION 
The HIV gag polyprotein contains at last 4 different 
cleavage sites. For conducting kinetic analysis, we used 
a chemically synthesized 72-amino acid polypeptide 
spanning just the p7 and pl proteins (Fig. 1A). No 
hydrolysis was observed in the absence of HIV-l pro- 
tease (Fig. 1B). The 72-amino acid polypeptide was hy- 
drolyzed by HIV-l PR, giving rise to two products as 
shown in the HPLC chromatogram (Fig. 1C). The hy- 
drolysis of this synthetic polypeptide was linear up to 
One cleavage product of the synthetic polypeptide 
eluting at 23% acetonitrile on a C, reverse-phase col- 
umn (Fig. lC), peak 1) was identified as the N-terminus 
of p7 by N-terminal sequencing of the first 35 amino 
acids, starting with MQRGN. The second cleavage 
product, which elutes slightly after the substrate at 3 1% 
acetonitrile (Fig. lC, peak 2) was sequenced up to 13 
amino acids. The sequence starting with FLGKI, as 
well as its molecular weight of 1980.4 Da, as deter- 
mined by mass spectroscopy, indicate hydrolysis of the 
peptide bond between amino acid 55 (N) and 56 (F) of 
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Fig. 1. (A) Structure of the 72-amino acid polypeptide. The 72-amino acid polypeptide was chemically synthesized and assayed in the absence of 
Zn*‘, unless indicated otherwise. The p7/pl cleavage site was deduced by N-terminal sequencing and mass spectrometric analysis of the hydrolysis 
products after RP-HPLC purification. (B,C) HPLC elution profiles of the 72-amino acid polypeptide and its cleavage products. 5 /Ig of the 72-amino 
acid polypeptide was assayed in the absence (B) and presence (C) of 5.3 ng of HIV-l protease. The time scale is given in minutes after injection, 
and the indicated gradient (--- -) is corrected for the void volume. Peaks 1 and 2 in C denote the product peaks, p7 and pl, respectively. 
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Fig. 2. (A) Time-course of p7/pl cleavage. An &fold volume of the standard assay, as described in section 2 containing 5,970 pmol of the synthetic 
polypeptide was incubated in a sealed tube at 37’C and in a closed incubator to minimize evaporation. After mixing, 10 ~1 were removed at the 
indicated time points, added to 90~1 of 1% TFA solution and analyzed by RP-HPLC. (B) pH titration of p7/pl cleavage. Enzyme activity at different 
pH values was tested at a final concentration of 4 M KCl, which was used instead of 0.75 M ammonium sulfate. (C) Salt titration of p7/pl cleavage. 
Increasing concentrations of KC1 (0) and ammonium sulfate (m), expressed in ionic strength, are plotted against enzyme activity. 
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the polypeptide (see Fig. 1A). This confirms the previ- 
ously predicted p7/pl cleavage site [7,8]. Under the con- 
ditions used, we did not detect any other cleavage prod- 
ucts. 
The pH optimum for proteolytic hydrolysis of the 
p7/pl cleavage site is 6.0 (Fig. 2B). The rate of cleavage 
increases with increasing ionic strength, with a more 
pronounced effect when salts possessing a high salting- 
out effect were used (Fig. 2C), which is in accordance 
with published data for HIV-l PR employing synthetic 
oligopeptide substrates [15,16]. For the p7/pl hydroly- 
sis, we obtained values of K,,, = 99 PM (k 8) and 
k,, = 0.152 s-l (+ 0.002) which are within the range 
reported for cleavage of various peptide substrates of 
HIV-l PR (Km = 5-1,250 ,uM and k,, = 0.01-6.8 s-’ 
[lo]). However, the turnover rates (k,,/K,J of the p7/pl 
and the pl/p6 cleavage sites are small, 1.56 mM_’ . SC’ 
(5 0.11) and 0.6 mM_’ . se1 [lo], respectively, indicating 
a rather low rate of cleavage of its parent protein, p15 
into p7, pl and p6, as compared to other sites within the 
pr55 . gag However, incubation of the gag polyprotein 
synthesized in vitro with purified HIV PR shows that 
the p6 and p7 proteins are processed faster than the p17 
and p24 proteins during the sequential cleavage reaction 
[17]. This apparent contradiction between the fast ap- 
pearance of p7 and p6 during polyprotein processing, 
and the low turnover rates of synthetic peptides corre- 
sponding to these cleavage sites, indicates that addi- 
tional or other parameters determine the order in which 
the proteins are processed. Therefore, it was of interest 
to test whether the secondary structure of p7 has an 
effect on the rate of cleavage. 
In the absence of EDTA and at neutral pH, addition 
of 2 2.2 molar equivalents of ZnCl, reconstitutes the 
structure of the mature p7 protein [11,18-201. One zinc 
atom is coordinated within each of the two Cys-X2-Cys- 
X,-His-X,-Cys motifs of p7 (Fig. lA), and the two zinc 
domains were found to be spatially close [21]. As shown 
in Table I, addition of 2.5 or 12.5 equivalents of zinc 
had no substantial effect on the hydrolysis of the p7/pl 
cleavage. It is possible that an enhanced enzyme activity 
induced by conformational changes of p7 complexed to 
Zn*’ was not detected ue to concomitant inhibition of 
the PR by Zn*+ [22] present in the assay. To test this, 
the polypeptide was substituted with 80 PM EDTA to 
maintain a stoichiometric number of Zn*+ binding (ch- 
elation) sites in the assay, and PR activity was measured 
by hydrolysis of a synthetic nona-peptide [13]. Under 
these conditions, inhibition of PR activity was not de- 
tected up to a concentration of 1 mM ZnCl, (data not 
shown). Therefore, we conclude that the hydrolysis of 
the p7/pl cleavage site is independent of the Zn*‘-in- 
duced conformation of the p7 protein. 
The data presented here confirm the p7/pl cleavage 
site to be a specific maturation site of HIV For hydrol- 
ysis, the native conformation of the p7-Zn*’ complex 
is not required in vitro. Furthermore, the ability of the 
HIV-l PR to hydrolyse the p7/pl scissile bond in the 
synthetic polypeptide, but not in a synthetic 1 l-amino 
acid oligopeptide substrate [lo], suggests that amino 
Table I 
p7/pl cleavage of denatured and reconstituted p7 
ZnCl, ZnCl, enzyme activity % of substrate 
(mM) (eq. of ~71~1)~ @mol/lS h)’ cleaved 
0 0 163 41 
0.1 2.5 197 49 
0.5 12.5 142 36 
“Final concentration in the assay. 
bZnCI, concentration in relation to the polypeptide concentration (40 
PM = 1 molar equivalent (eq.)) 
‘Enzyme assays were carried out for 15 h at 37°C in the absence of 
EDTA. 
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acids relatively far away from the cleavage site contrib- 
ute to the recognition of an amino acid sequence as a 
substrate. Taken together, recognition of this cleavage 
site by the HIV-l PR is determined by the primary 
structure of the substrate. The Zn2’-induced conforma- 
tion of the p7 protein has no effect on the hydrolysis of 
its C-terminal cleavage site. 
AcknowZedgements: We thank J.K. Kraus for kindly providing pro- 
tease inhibitors, Y. Kim for sequencing, and A.R. Kimmel and S. 
Oroszlan for their comments on the manuscript. E.M.W. was sup- 
ported in part by a fellowship from ANRS, France. 
REFERENCES 
[l] Rey, F., Barre-Sinoussi, F. and Chermann, J.C. (1987) Ann. Inst. 
PasteurNirol. 138, 161-168. 
[2] Krausslich, H.-G. and Wimmer, E. (1988) Annu. Rev. Biochem. 
51, 101-754. 
[3] Krlusslich, H.-G., Oroszlan, S. and Wimmer, E. (1989) Current 
Communications in Molecular Biology: Viral Proteinases as Tar- 
gets for Chemotherapy, Cold Spring Harbor Laboratory Press, 
Cold Spring Harbor, NY. 
[4] Skalka, A.M. (1989) Cell 56, 911-913. 
[5] Oroszlan, S. and Luftig, R.B. (1990) Retroviral Proteinases. in: 
Current Topics in Microbiology and Immunology: Retroviruses 
- Strategies of Replication, vol. 157 (Swanstrom, R. and Vogt, 
P.K. eds) pp. 153-185, Springer-Verlag, Heidelberg. 
[6] Miller, M., Schneider, J., Sathyanarayana, B.K., Toth, M.V., 
Marshall, G.R., Clawson, L., Selk, L., Kent, S.B.H. and 
Wlodawer, A. (1989) Science 246, 1149-l 152. 
[7] Henderson, L.E., Copeland, T.D., Sowder, R.C., Schultz, A.M. 
and Oroszlan, S. (1988) in: Human Retroviruses, Cancer, and 
AIDS: Approaches to Prevention and Therapy (D, Bolognesi ed.) 
pp. 135-147, Liss, New York. 
@I 
[91 
[lOI 
illI 
WI 
P31 
[I41 
iI51 
[lb1 
[I71 
WI 
[I91 
[201 
WI 
WI 
Henderson, L.E., Bowers, M.A., Sowder, R.C., Serabyn, S.A., 
Johnson, D.G., Bess Jr., J.W., Arthur, L.O., Bryant, D.K. and 
Fenselau, C. (1992) J. Virol. 66, 18561865. 
Darke, P.L., Nutt, R.F., Brady, S.F., Garsky, V.M., Ciccarone, 
T.M., Leu, C.-T., Lumma, P.K., Freidinger, R.M., Veber, D.F. 
and Sigal, I.S. (1988) Biochem. Biophys. Res. Commun. 156, 
297-303. 
Tiizser, J., Blaha, I., Copeland, T.D., Wondrak, E.M. and 
Oroszlan, S. (1991) FEBS Lett. 281, 77-80. 
DeRocquigny, H., Ficheux, D., Gabus, C., Fournie-Zaluski, 
MC., Darlix, J.L. and Roques, B.P. (1991) Biochem. Biophys. 
Res. Commun. 180, 1010-1018. 
Louis, J.M., McDonald, R.A., Nashed, N.T., Wondrak, E.M., 
Jerina, D.M., Oroszlan, S. and Mora, P.T. (1991) Eur. J. Bio- 
them. 199, 361-369. 
Wondrak, E.M., Copeland, T.D., Louis, J.M. and Oroszlan, S. 
(1990) Anal. Biochem. 188, 82-85. 
Henderson, P.J.F. (1972) Biochem. J. 127, 321-333. 
Wondrak, E.M., Louis, J.M. and Oroszlan, S. (1991) FEBS Lett. 
280, 344-346. 
Tropea, J.E., Nashaat, N.T., Louis, J.M., Sayer, J.M. and Jerina, 
D.M. (1992) Bioorg. Chem. 20, 67-76. 
Tritch, R.J., Cheng, E.S.E., Yin, F.H. and Erickson-Viitanen, S. 
(1991) J. Virol. 65, 922-930. 
Sorovoy, A., Dannull, J., Moelling, K. and Jung, G. (1993) J. 
Mol. Biol. 229, 94104. 
South, T.L. and Summers, M.F. (1993) Protein Sci. 2, 3-19. 
Summers, M.F., South, T.L., Lee, B. and Blake, P.R. (1993) J. 
Cell. Biochem. 48, 245. 
Morellet, N., Jullian, N., DeRoquigny, H., Maigret, B., Darlix, 
J.L. and Roques, B.P. (1992) EMBO J. 11, 3059-3065. 
Zhang, Z.Y., Reardon, I.M., Hui, J.O., O’Connell, K.L., Poor- 
man, R.A., Tomasselli, A.G. and Heinrickson, R.L. (1991) Bio- 
chemistry 30, 8717-8721. 
24 
